EICHORPublic-registry site landscape for NCT03435848, “Efficacy and Safety of BST-236 in Newly Diagnosed Acute Myeloid Leukemia Patients, Unfit for Standard Induction Therapy”, a Acute Myeloid Leukemia study sponsored by BioSight Ltd.. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT03435848 (registry record) |
| Study title | Efficacy and Safety of BST-236 in Newly Diagnosed Acute Myeloid Leukemia Patients, Unfit for Standard Induction Therapy |
| Official title | A Phase 2b Open-Label, Single Arm, Multi-Center Study to Assess the Efficacy and Safety of BST-236 as a Single Agent in Adults With Newly-Diagnosed Acute Myeloid Leukemia (AML), Not Eligible for Standard Induction Therapy |
| Sponsor | BioSight Ltd. |
| Condition(s) | Acute Myeloid Leukemia |
| Phase | PHASE2 |
| Listed sites | 16 |
| Site countries | United States, Israel |
Patient-friendly overview of this study: eichor.com/study/NCT03435848.
Eichor generates a preliminary site-risk snapshot for NCT03435848 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
Other Acute Myeloid Leukemia trials
← Eichor home · All tracked trials · Acute Myeloid Leukemia studies · Weekly briefs
